Form 4: Cadrenal CEO Quang Pham Executes Stock Sale Plan

Cadrenal Therapeutics Chairman and CEO Quang Pham sold 18,124 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Quang Pham, Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., sold a total of 18,124 shares of common stock.
• The sales occurred across three dates: June 11, 2026 (1,462 shares), June 12, 2026 (12,996 shares), and June 15, 2026 (3,666 shares).
• The transactions were executed at weighted average prices of $4.12, $3.94, and $3.58 per share, respectively.
• The sales were conducted pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025.
• Following these transactions, the reporting person retains direct ownership of 132,715 shares and indirect ownership of 200,000 shares via The PVBQ Living Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be optically negative, the use of a pre-planned 10b5-1 arrangement suggests the sales are for personal financial planning rather than a reaction to company-specific news.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale of shares by the CEO and Chairman may be perceived by some investors as a lack of confidence in the short-term price appreciation of the stock.

Risks

• Continued selling pressure from insiders could negatively impact the stock price.
• The reliance on a single individual for the roles of Chairman, CEO, and Interim CFO presents key-person risk.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling under 10b5-1 plans is a standard corporate practice for liquidity and diversification, and is generally viewed as less significant than discretionary open-market sales.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage equity holdings while maintaining regulatory compliance.
• The volume of shares sold represents a small fraction of the total holdings of the reporting person, which is consistent with typical executive diversification strategies.

Related Party Transactions

• The reporting person is the Trustee of The PVBQ Living Trust, which holds 200,000 shares of the issuer.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the impact is mitigated by the pre-planned nature of the sales.

Next Steps

• Continued monitoring of future Form 4 filings to track any further changes in insider holdings.

Key Dates

Keywords

Cadrenal Therapeutics, CVKD, Insider Trading, Form 4, Quang Pham, Rule 10b5-1